HomeMy WebLinkAboutAgenda - 03-21-2023; 8-g - Alliance Health Board of Directors - Appointment 1
ORANGE COUNTY
BOARD OF COMMISSIONERS
ACTION AGENDA ITEM ABSTRACT
Meeting Date: March 21, 2023
Action Agenda
Item No. 8-g
SUBJECT: Alliance Health Board of Directors - Appointment
DEPARTMENT: Board of Commissioners
ATTACHMENT(S): INFORMATION CONTACT:
Recommendation Clerk's Office, 919-245-2130
PURPOSE: To approve an appointment to the Alliance Health Board of Directors.
BACKGROUND: Orange County appoints two (2) members to the Alliance Health Board of
Directors, including one member of the Orange County Board of County Commissioners and one
Orange County resident. The application process for the resident position is managed by Alliance
Health staff, and the Board of Directors reviews the applications and makes recommendations to
the Board of County Commissioners.
On March 2, 2023, the Alliance Health Board of Directors voted unanimously to recommend the
following appointment:
NAME POSITION TYPE OF EXPIRATION
DESCRIPTION APPOINTMENT DATE
TERM
Dr. Michael Orange County First Full Term 03/31/2025
Joseph Representative
FINANCIAL IMPACT: There is no financial impact associated with this item.
SOCIAL JUSTICE IMPACT: The following Orange County Social Justice Goal is applicable to
this item:
• GOAL: ENABLE FULL CIVIC PARTICIPATION
Ensure that Orange County residents are able to engage government through voting and
volunteering by eliminating disparities in participation and barriers to participation.
ENVIRONMENTAL IMPACT: There is no Orange County Environmental Responsibility Goal
impact associated with this item.
RECOMMENDATION(S): The Manager recommends that the Board approve the recommended
appointment to the Alliance Health Board of Directors.
2
All Offices:
Mi
lance
(919) 651-8401
H ea I t h Online:
All ianceH ealth E'Ian.Org
March 10, 2023
Sent via Electronic Mail
Orange Board of County Commissioners
Attn: Jamezetta Bedford, Chair
300 West Tryon Street
P.O. Box 8181
Hillsborough, NC 27278
ibedford(c�orangecountync.gov
RE: Request for Appointment
Dear Chair Bedford,
I am pleased to share with you and your colleagues that the Alliance Health (Alliance) Board of Directors
voted unanimously at its March 2, 2023, meeting to recommend Michael C. Joseph for appointment to
Alliance's Board. If appointed, Dr. Joseph's first term would be in the second Orange seat on Alliance's
board, which expires March 31, 2025.
Dr.Joseph's medical background and experience in health services, especially for underserved populations
closely aligns with Alliance's Mission, Vision, and Values. He would provide beneficial insight in
understanding the challenges faced to provide medically necessary services for individuals Alliance serves.
This insight is critical as North Carolina considers Medicaid expansion and as Alliance prepares to operate
as a Tailored Plan.
We believe Dr. Joseph has a unique perspective and that his appointment to Alliance's Board would help
Alliance fulfill its Mission: to improve the health and well-being of the people we serve by ensuring highly
effective, community-based support and care. We respectfully encourage his appointment.
Best Regards,
Lyn e W. Nelson
Board Chair
/vi
enclosures
cc: Robert Robinson, Alliance CEO
Jean Hamilton, Orange County Commissioner/Alliance Board Member
Laura Jenson, Clerk to the Orange Board of County Commissioners
Tara May, Deputy Clerk to the Board
Home Office:5200 West Paramount Parkway,Suite 200,Morrisville,NC 27560
Cumberland Office:711 Executive Place,Fayetteville,EJC 28305 ' \
Johnston Office:521 N. Brightleaf Boulevard,Smithfield,MC 27577 NCCtA NCC�A
Mecklenburg Office:3205 Freedom Drive,Suite 1800,Charlotte,NC 28208LONG-TERM MANAG€DSEHAVIOAAt
SERVICES&SUPPONS +'EALTNCARE ORGANIZATION
Fljll
3
■
'� ��� Please return application and
supporting documents to:
Health Alliance Health
Attn:Veronica Ingram, Clerk to the Board
5200 W. Paramount Pkwy, Ste. 200
BOARD MEMBERSHIP APPLICATION Morrisville, NC 27560
(Application must be signed before submitting. All or sign, scan and submit electronically
information on this document will be released to the with supporting documents to
public upon request.) Vingram@A]IianceHeaithPlan.org.
Contact Information
Name: 4 i t L►Atl C . ✓ozo pL; A4D) M PH
Primary Phone Number: q /1 7- 3— 3 9 0 7
r,r-Go µ
Primary Email Address: J%A bs'Q
j, N►e1� h .
Street Address: ,S^D 6 Sr'vvi✓
City-4;11S'6�'°�',��' County: OvP-06-J'a— State: NC zip: 2-1 til
Eligibility to Serve
The Alliance Board holds regular monthly meetings. Some meetings take place at one of the community
offices; otherwise, meetings occur at the home office in Morrisville. Board members participate on 2-3
subcommittees based on their expertise and interests. Most Board members dedicate between 6-10 hours
per month on Board activities, more if they choose to serve on special projects.
Candidates for Board membership must be residents from one of the counties served by Alliance.
Employees, family members of employees, or volunteers of provider agencies or vendors contracted with
Alliance, or persons with a financial interest or ownership in any such agency or vendor, are not eligible to
serve.
While Board members are appointed because they represent a certain community, once on the Board, their
responsibility is to all individuals served by Alliance.
Are you a provider that has a contract or referral relationship with Alliance or do you work for or serve on a
board of a provider that has a contract or referral relationship with Alliance? If so, please provide the name of
the provider and your role.
Do you have a contract with another LME/MCO? If so, please explain. IVC7
Are you a Lobbyist under Chapter 120C of the General Statutes? If so, under what capacity? No
Rvsd 12/2/2021
4
Desire to Serve
Based on your qualifications and experience, briefly describe how you can contribute as a Board member to
help Alliance achieve its vision to be a leader in transforming the delivery of whole person care in the public
sector[alliancehealthlan.or labout/ overnance/board-of-directorsl]:
•.eta-•rl�-✓vie[ �c�,i�vl a ,oj., A--�.,.a� d�c�►�e,.�'A-•-ems *�+, *•ta.�
Relevant Experience and Expertise
Please submit a current CV/resume with education, work experience, publications/presentations,
awards/honors with your application.
Current Occupation (if applicable). X#'4-l Y r_,4 (2
Place of Business/Employment(if applicable): NIA
List any Cumberland, Durham, Johnston, Mecklenburg, Orange or Wake county committees or boards on
which you presently serve: /V p h g
Please list any groups, organizations, or key decision-makers in North Carolina and beyond that you could
serve as a liaison to/advocate for on behalf of Alliance Health.
Please review the categories below, which specify current membership requirements, and check the
applicable boxes:
Consumer or family member representing the interest of individuals with mental illness, intellectual
or other developmental disabilities or substance use
CFAC (Consumer and Family Advisory Committee) member
An individual with health care expertise and experience in the fields of mental health, intellectual or
other developmental disabilities or substance use/addiction services
An individual with financial expertise
X An individual with provider experience in a managed care environment
A representative of people with mental health, intellectual/developmental disabilities, or substance
useladdiction
Alliance is seeking individuals with experience and expertise in strategic areas. Please review the areas
below and check any applicable box(es):
xHuman Resources/Talent Management
Insurance/Managed Care Background
X Leadership/Management Experience
Physical Health Background/Expertise
Political/Community Connections
V Technology/Data Analytics Experience
Please tell us anything else you would like to share (feel free to include a cover letter with application).
h,. �J• I►..���a a.C. �-•�A. t�i G.e. T f�,.�'� of a �v U�'-1 h co
s,.�r�•y-; I y /r'aa.��*=� �.s.J,'/�� /..,...•-.-�► tly 1•�,�•�t.,� lA..�...r�
44.
�►��e--r.. �' I'�� Gv 1,..3►-a'�. vl��.h-s s�. � Gam".�P�.'+.�.[G�1�k l.)• I
5
Next Steps
• Completed applications will be reviewed by our legal and compliance team for eligibility and potential
conflicts of interest within 30 days.
• You will be contacted regarding the status of your,application and if applicable, to arrange an
interview date.
NOTE: Final decisions on appointments to the Alliance Board are made by the respective Boards of County
Commissioners_ If appointed, all future communications will be via an agency-issued email account.
Applicant's Signature: A�A-ra
Date: jG�ti► r.. a-✓j 13
3
Rusd 12!2!2021
6
Michael C.Joseph,MD,MPH,FACPM Curriculum Vitae
Michael C. Joseph, MD,MPH, FACPM
506 Silver Fox Circle
Hillsborough,NC 27278
mci osePhmdAnc.rr.com
919.923.3907
AREAS OF SPECIAL FOCUS: Drug Safety
Medical Informatics
Preventive Medicine
Preventive Medicine
KEY SHILLS: Effective Project Management
Works efficiently alone or in a matrix structure
Process development and employee training/mentoring
Ability to visualize and implement efficient techniques
Innovative drug safety and medical information
procedures
PROFESSIONAL AFFILIATIONS:
Board Certification: General Preventive Medicine and Public Health
Member: American College of Preventive Medicine
EDUCATIONAL HISTORY:
1984-1985 POSTDOCTORAL: University of California
School of Public Health
Los Angeles,CA
Degree: M.P.H.,Health Services
1983-1984 SPECIALTY TRAINING: Practicurn Year Resident
(Preventive Medicine) Department of Health Services
Los Angeles,CA
1976-1978 SPECIALTY TRAINING: Internship and Assistant Residency in Pediatrics
(Pediatrics) Children's Hospital
Los Angeles,CA
1972-1976 POSTGRADUATE: University of California
School of Medicine
San Francisco,CA
Degree: M.D.
1960-1965 Harvard College
Cambridge,MA
Degree: A.B. (Mathematics)
12 January 2023 Page 1 of 8
7
Michael C.Joseph,MD,MPH,FACPM Curriculum Vitae
EMPLOYMENT HISTORY:
July 2009—February 2016 Chief Executive Officer
MCJ Drug Safety Consulting,LLC
Hillsborough,NC 27278
Duties: Medical Monitoring
Medical Monitor Training&Supervision
Protocol Reviews
Investigator Site Procedures
Clinical References
Project Team Training
Adverse Event Monitoring
MedDRA and WHO-DRUG Dictionaries Q/C
Periodic Data Reviews
Data Safety Monitoring Board(DSMB)Preparation
Medical Monitoring Projects:
Attention Deficit Hyperactivity Disorder;Tinea
Infections.
September 2005-June 2009 Senior Director,Medical Affairs
INC Research,Inc.
Raleigh,NC 27609
Duties: Medical Monitoring/Consultation.
Clinical Data Reviews.
Staff Training.
Medical Monitoring Projects: Attention Deficit Hyperactivity Disorder;
Blepharospasm;Cervical Dystonia;Diabetic Peripheral
Neuropathy;Fibromyalgia; Generalized Anxiety
Disorder;Insomnia;Insomnia in Attention Deficit
Hyperactivity Disorder;Lennox-Gastaut Syndrome;
Major Depressive Disorder;Pediatric Constipation;
Restless Legs Syndrome.
December 1998-September 2005 President&CIO
Coding Plus
Hillsborough,NC 27278
Duties: Drug Safety and Medical Informatics Consulting.
Software Development Project Leadership.
MedDRA Implementation Support.
Direction of a Virtual Service Bureau.
Staff Training.
12 January 2023 Page 2 of 8
8
Michael C.Joseph,MD,MPH,FACPM Curriculum Vitae
February 1998-December 1998 Sr.Director-Medical Information, Safety Surveillance
Agouron Pharmaceuticals,Inc.
Agouron Pharmaceuticals,Inc.
San Diego,CA 92121
Duties: Development of a Drug Safety Unit.
Pharmacovigilance assessments.
Selection and implementation of a new adverse event
data management system.
Supervision of coding in COSTART,MEDDRA 1.5,
and the WHO-DRL dictionaries.
Medical Consultation.
Staff Training.
May 1992-January 1998 VP,Development and Information Services
Practical Information Resources,Inc. (PIRI)
Durham,NC 27722-1398
Duties: Pharmaceutical Industry Consultation.
Expert Systems Software Development.
Adverse Drug Event Surveillance Training.
Dictionary Support Services.
July 1985-May 1992 Associate Director for Medical Epidemiology
Division of Epidemiology, Surveillance&
Pharmacoeconomics(ESP)
Burroughs Wellcome Co. (BW Co.)
Research Triangle Park,NC 27709
Duties: Management of the Division in the Director's absence.
Direct supervision of two sections:Data Management
Systems and Product Surveillance.
Backup supervision of 2 sections:Epidemiology and
Pharmacoeconomics.
Development and supervision of a Divisional Quality
Assurance Team.
Task Force leadership and contract management of the
Retrovir® (AZT)Treatment IND(February
1987-March 1988),and the Exosurf®Pediatric
Treatment IND(May 1989-May 1992).
Project responsibility for several post-marketing
surveillance studies.
Management of adverse drug experience reports on all
Burroughs Wellcome Co.marketed drugs.
12 January 2023 Page 3 of 8
9
Michael C.Joseph,MD,MPH,FACPM Curriculum Vitae
Medical Consultation.
Staff Training.
April 1980-May 1983 Dr.Mike's Place
Long Beach,CA
Solo Practice Pediatrics
LA County-USC Medical Center Pediatric Pavilion
Los Angeles,CA
Emergency Pediatrics
TRAINING:
Developed industry courses for public and on-site delivery:
1993-1995 Adverse Drug Event Management PIRIcourse'm
1999 Expert Coding for the New Millennium: MedDRA&WHO-DRUG
2000-2006 MedDRA Dictionary Management Courses(public,on-site,webinar)
MedDRA 102-Concise Dictionary Overview
MedDRA 202-Coding Tutorial
MedDRA 203 -Data Extraction Tutorial
MedDRA 204-Dictionary Management Tutorial
DRUG SAFETY PROJECTS(Coding Plus):
Clinical Studies
Adverse Event Monitoring Procedures
MedDRA Query Creation
Labeling Classifications
Dictionary Management
Adverse Event Coding-COSTART,WHO-ART,and MedDRA
Medication Coding—BNF,WHO-DRL
Legacy Conversions—Clinical and Safety databases
Software(MedDRA Coding Workbench")
Informatics design,testing,and validation support of a web based system for:
- multiversion coding,consistency review,and version impact analysis;
- user-specific knowledge base maintenance.
DRUG SAFETY PROJECTS(PERI):
Clinical Studies
Project References
Periodic Coding Consistency Reviews
Postmarketing Surveillance
Labeling References
Case Review Conferences
12 January 2023 Page 4 of 8
10
Michael C.Joseph,MD,MPH,FACPM Curriculum Vitae
Dictionary Support Services
Legacy Data Conversions
Expanded Synonym Tables
Periodic Database Audits
General Consulting
Global Clinical Data Management System Specifications
Coding Conventions
SOPS
Medical Informatics
Expert Consultant to Quintiles,Inc.on the Food&Drug Administration's"Development of
Standardized Nomenclature"contract(June 1993-January 1996).
Authored the White Paper: "Practical Issues in developing a MEDDRA Autoencoder"
for FDA(January 1995).
Medical informatics review of COSTART,WHO-ART,ICD-9-CM, SNOMED,and
UMLS for the Council of International Organizations for the Medical Sciences
(CIOMS). Authored the White Paper:"Functional Thesaurus Review". (May 1994).
Software
Invited presentation at FDA on"Autoencoding of Periodic Safety Reports".
Demonstration of the PIRIcodeTM Adverse Drug Event Autoencoder and Discussion of
data mining techniques(February 1995).
Creation of ad-hoc autoencoders for FDA's comparison of COSTART,WHO-ART,and
MEDDRA. Design of six knowledge bases spanning"Eye Disorders" and"Psychiatric
Disorders"in the three thesauri(July 1994).
Launch of the PIRIcodeTM Expert System Autoencoder for the translation of adverse drug
event verbatim terms into COSTART,WHO-ART,and in-house thesauri. (March 1993)
DRUG SAFETY PROJECTS(BW Co.):
Large,long term,analyses of the safety profiles of OTC drugs using Public Health Departments.
Validation of diagnoses in the Medicaid database.
International study of the adequacy of medical data and validity of inferred diagnoses.
An outpatient study into the prevalence,incidence,and treatment of genital herpes,as well as the psychosocial
effects of the disease.
Designed and programmed an automated COSTART coding scheme of raw(verbatim)terms from adverse drug
event(ADE)reports.
Creation of automated and hardcopy drug safety references for reliable risk analysis
(syndrome definition,trend analysis,automated periodic reporting,and signal
generation).
12 January 2023 Page 5 of 8
11
Michael C.Joseph,MD,MPH,FACPM Curriculum Vitae
PRESENTATIONS:
March 2004: "Managing MedDRA in Clinical Studies". Barnett International Adverse Events—
Insights into the"Tome",International Guidelines,MedDRA, Signaling,Causality Assessment,
and Risk Management.Philadelphia,PA.
November 2003: "Cross-dictionary Event Classification and Monitoring". Barnett International
Signaling Methods and Program Design. Philadelphia,PA.
April 2003: "MedDRA Dictionary Maintenance: Practice vs.Promise". Drug Information
Association CDM Meeting. Philadelphia,PA.
July 2002: "MedDRA Pharmacovigilance—Promise and Perils". Center for Business Intelligence
(CBI)Third Forum on Pharmacovigilance.Philadelphia,PA.
June 2002: "Practical Techniques for Effective MedDRA Dictionary Management". Drug
Information Association Annual Meeting. Chicago,IL.
March 2002:"Autoencoding:Achieving the Clinical Data Management Payoff'.Drug Information
Association CDM Meeting. Charleston, SC.
October 2001:"Medical Informatics Based Expert MedDRA Knowledge Management". Drug Information
Association MedDRA Workshop. Baltimore,MD.
November 2000: "Fulfilling the MedDRA Promise—A Practical Crash Program". Drug Information
Association European CDM Meeting.London,UK.
June 2000: "MedDRA Legacy Conversion-Project Planning". Clintrace®User Group. San Diego,CA.
November 1999: "MedDRA Implementation Update". 3"Annual DIA Workshop: "West Coast DIA
Management&Biostatistics". San Jose,CA.
September 1999: "Implications and Outcomes of Using MedDRA on Clinical Study Data". Society for Clinical
Data Management Fall Conference". Chicago,IL.
April-May 1999: "Developing a Strategic Plan for MedDRA Implementation". Lecture in six cities as part of
DOMAIN Pharma,Inc. Seminar: "MedDRA:Facing the Challenge".
April 1999: "Issues in the Adoption of MedDRA-Autoencoding". Drug Information Association CDM
Meeting. Washington,D.C.
December 1998: "MedDRA Conversion Issues: Small Company Solutions". The 2nd Annual DIA
Workshop on West Coast Data Management and Biostatistics. San Jose,CA
October 1996: "Improving Clinical Trial Adverse Event Coding-Practical Planning and Control
Strategies". Society for Clinical Data Management Fall Conference. Baltimore,MD.
March 1996: "Improving Clintrace® coding performance using enhanced thesaurus reference
files". BBN Clintrace® User Group Meeting. Philadelphia,PA.
March 1995: "Getting to New-ART". Drug Information Association CDM Meeting. Philadelphia,
PA. (with Katherine Schoeffler)
12 January 2023 Page 6 of 8
12
Michael C.Joseph,MD,MPH,FACPM Curriculum Vitae
March 1995:"PIRI's evaluation of MEDDRA". COSTART Users'Group. Drug Information
Association CDM Meeting. Philadelphia,PA. (with Katherine Schoeffler)
June 1994: "Automated Coding and Extraction". Association of Clinical Data
Management. Birmingham,UK.
June 1994: "The Use of Automatic AER Coding Programs". Drug Information Association Annual
Meeting. Philadelphia,PA.
March 1994: "Don't Code ... Communicate". Drug Information Association CDM
Meeting. Philadelphia,PA.
July 1993: "Issues in the Collection and Coding of Adverse Reaction Data". Drug Information
Association Annual Meeting,Washington,D.C.
November 1992: "Expert Systems Coding and Translation of Adverse Drug Reactions". Drug
Information Association European CDM Meeting,Nwoordwijk,The Netherlands.
June 1992: "A Practical Expert System for Classification of Medical Events". COSTART Users' Group. Drug
Information Association Annual Meeting. San Diego,CA.
October 1991: "Did My Drug Cause This? -An Industrial Perspective". Drug Information Association
Meeting,New Orleans,LA.
September 1991: Two lectures in the course "Organizing and Administering an Adverse Drug Reaction
Programme".Amsterdam. The Center for Professional Advancement.
September 1990: "Post-Marketing Surveillance". Wexner Symposium,Children's Hospital,Columbus,OH.
March 1990:Two lectures in the course "Organizing and Administering an Adverse Drug Reaction
Programme". Amsterdam. The Center for Professional Advancement.
June 1989: "The Development of a Labeled Adverse Drug Experience Database". Drug Information
Association Annual Meeting,Boston,MA.
April 1989: "Implementation of an Automated Coding Scheme using COSTART". Drug Information
Association Meeting,Philadelphia,PA.
July 1988:Pilot talk-"An Automated Coding Scheme Using COSTART". Drug Information Association
Annual Meeting,Toronto,CANADA.
September 1987: "The Retrovir Experience". 3rd International Pharmacoepidemiology Conference.
Minneapolis,MN.
May 1987:Lecture"Drugs in Special Populations(Pediatrics)"in the course "Methods and Issues in
Pharmacoepidemiology". University of North Carolina,Chapel Hill,NC.
May 1986:Presentation at the FDA- "Status of the Burroughs Wellcome Co.'s Rheumatoid Arthritis
Azathioprine Registry".
May 1986:Lecture- "Epidemiologic Intelligence. Voluntary Reporting of Adverse Drug Events"in the course
"Methods and Issues in Pharmacoepidemiology". University of North Carolina,Chapel Hill,NC.
12 January 2023 Page 7 of 8
13
Michael C.Joseph,MD,MPH,FACPM Curriculum Vitae
April 1986: "Determinants of Consistency in the Epidemiologic Monitoring of Adverse Drug Events".Porta
MS,Joseph MC,Doi PA,Tilson HH,Andrews EB. The Third Annual National Preventive Medicine Meeting,
Atlanta,GA.
PUBLICATIONS:
1. Joseph,MC. "MedDRA Conversion Issues: Small Company Options". DIA Forum,Vol.35,No.2,pg. 30,
April 1999. (Summary of presentation at the 2°a Annual DIA Workshop: "West Coast Data Management&
Biostatistics". San Jose,CA. December 1998.
2. Joseph,MC The College-AidTM Health Care Guide,Practical Information Resources,Inc.,First Edition
1990,Second Edition 1992.
3. Andrews EA,Joseph MC,Magenheim MJ,Tilson HH,Doi P, Shultz M. "Post-Marketing Surveillance
Study of Permethrin Cream Rinse". AM J Public Health. 1992; 82:857-861.
4. Joseph MC, Schoeffler KM,Nissman EF,Doi PA,Yefko HF,Engle CR. "An Automated Coding Scheme
using COSTART". Drug Information Journal,Vol.25,No. 1,pp. 97-108, 1991.
5. Strom BL,Carson JL,Halpern AC, Schinnar R, Snyder ES,Shaw M,Tilson HH,Joseph MC,Dai WS,
Chen D, Stem RS,Bergman U, Stolley PD. "A Population-Based Study of Stevens-Johnson Syndrome:
Incidence and Antecedent Drug Exposures". Archives of Dermatology,Vol. 127,pp. 831-838, 1991.
6. Strom BL,Carson JL,Halpern AC, Schinnar R, Snyder ES, Stolley PD, Shaw MS,Tilson HH,Joseph MC,
Dai WS,Chen D, Stem RS,Bergman U,Lundin F. "Using a Claims Database to Investigate Drug Induced
Stevens-Johnson Syndrome". Statistics and Medicine,Vol. 10,pp. 565-576, 1991.
7. Lombardy L,Tilson H,Joseph M,Andrews E,Doi P,Long W. "Exosurf® Pediatric Treatment IND:A
Regulatory Mechanism to Make Surfactant Available to Infants with RDS". Neonatal Intensive Care,pp.
24-27,May/June 1990.
8. Curtis P,Okin M,McGaghie W,Resnick J.,Joseph MC,Davis G and the Herpes Collaborative Study
Group. "A Pilot Study of Prevalence of Herpes Genitalis Among Selected Groups of Patients Seeking Care in
a Family Practice Center". Family Medicine,Vol.22,No. 6,pp.456-461, 1990.
9. Kirk EL,Collins EG,Joseph MC et al. "Retrovir® (zidovudine),A Unique Drug Information Challenge".
Drug Information Journal,Vol.23,No.2,pp.257-266, 1989. (Winner:Donald E.Francke Award of the Drug
Information Association).
10.Joseph MC,Creagh-Kirk T. "Retrovir® The Challenge of Postmarketing Surveillance" in Proceedings of the
3rd International Pharmacoepidemiology Conference,Minneapolis, 1987. Lewis Publishing Company,
Minneapolis, 1989.
12 January 2023 Page 8 of 8